I. ROYALTY PHARMA is the premier R&D partner for the biopharmaceutical industry.
II. R&D PARTNERSHIPS are a unique form of capital. They leverage a single, at-risk, development-stage program while still achieving a highly competitive cost of capital compared with equity and debt instruments that are typically tied to all assets in a company.
III. ROYALTY PHARMA shares the same multi-year investment perspective as our partners: we understand that positive investment returns require clinical, regulatory, and commercial success.
IV. WE PROVIDE compelling cost of capital for highly innovative development-stage medications across all therapeutic areas and for companies of all sizes.
V. ROYALTY PHARMA can provide funding at scales relevant to both smaller, focused development programs as well as global pharmaceutical companies pursuing the largest, highest-complexity, and most capital-intensive development programs.
VI. WE PARTNER with small to medium-size companies looking to maximize value by retaining full global ownership of their pipeline through regulatory approval and launch.
VII. WE ACT as a passive partner for companies with full operational capabilities, or take a more active role when externalized funding and clinical trial execution are required.
Funding of late-stage pharmaceutical R&D is core to Royalty Pharma’s strategy.